p53: oncogene or anti-oncogene?

p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours

“…SCC; Squamous cell carcinoma. detected immunohistochemically (Lane and Benchimol, 1990). In our study, p53 was expressed in 65 per cent of the tumours, consistent with previous reports of p53 expression in head and neck.…”

p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours

“…SCC; Squamous cell carcinoma. detected immunohistochemically (Lane and Benchimol, 1990). In our study, p53 was expressed in 65 per cent of the tumours, consistent with previous reports of p53 expression in head and neck.…”

Numerical aberration and point mutation ofp53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: Analysis by fluorescencein situ hybridization (FISH) and PCR-SSCP

“…One sample had a mutation in exon 8, which was not found by Shiao et al (1994). Our results might also be in good agreement with the findings that the mutated gene product accumulates in the nucleus through binding to other oncogenic proteins or by prolonged half-life (Lane and Benchimol, 1990;Finlay et al, 1988). Indeed, point mutations have been identified in respective p53 genes in a variety of malignancies, including esophageal (Bennett et al, 1992), breast (Jacquemier et al, 1994) and colon (Dix et al, 1994) cancers known to express p53 protein.…”

ZetaSuite, A Computational Method for Analyzing Multi-dimensional High-throughput Data, Reveals Genes with Opposite Roles in Cancer Dependency

“…In fact, while wildtype TP53 always gave rise to a positive dependency score, reflecting its tumor suppressor function, mutant TP53 produced a negative cancer dependency score, indicating its oncogenic role in those tumor cells (Fig. 6g,h), which is in full agreement with the known functions of wildtype and mutant p53 in tumorigenesis 44 . Most interestingly, as exemplified with MDM2 , we observed that multiple cancer checkpoint genes are also linked to either low CNV or low expression (see Fig.…”

p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours

“…SCC; Squamous cell carcinoma. detected immunohistochemically (Lane and Benchimol, 1990). In our study, p53 was expressed in 65 per cent of the tumours, consistent with previous reports of p53 expression in head and neck.…”

Numerical aberration and point mutation ofp53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: Analysis by fluorescencein situ hybridization (FISH) and PCR-SSCP

“…One sample had a mutation in exon 8, which was not found by Shiao et al (1994). Our results might also be in good agreement with the findings that the mutated gene product accumulates in the nucleus through binding to other oncogenic proteins or by prolonged half-life (Lane and Benchimol, 1990;Finlay et al, 1988). Indeed, point mutations have been identified in respective p53 genes in a variety of malignancies, including esophageal (Bennett et al, 1992), breast (Jacquemier et al, 1994) and colon (Dix et al, 1994) cancers known to express p53 protein.…”

ZetaSuite, A Computational Method for Analyzing Multi-dimensional High-throughput Data, Reveals Genes with Opposite Roles in Cancer Dependency

“…In fact, while wildtype TP53 always gave rise to a positive dependency score, reflecting its tumor suppressor function, mutant TP53 produced a negative cancer dependency score, indicating its oncogenic role in those tumor cells (Fig. 6g,h), which is in full agreement with the known functions of wildtype and mutant p53 in tumorigenesis 44 . Most interestingly, as exemplified with MDM2 , we observed that multiple cancer checkpoint genes are also linked to either low CNV or low expression (see Fig.…”

p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours

“…SCC; Squamous cell carcinoma. detected immunohistochemically (Lane and Benchimol, 1990). In our study, p53 was expressed in 65 per cent of the tumours, consistent with previous reports of p53 expression in head and neck.…”

Numerical aberration and point mutation ofp53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: Analysis by fluorescencein situ hybridization (FISH) and PCR-SSCP

“…One sample had a mutation in exon 8, which was not found by Shiao et al (1994). Our results might also be in good agreement with the findings that the mutated gene product accumulates in the nucleus through binding to other oncogenic proteins or by prolonged half-life (Lane and Benchimol, 1990;Finlay et al, 1988). Indeed, point mutations have been identified in respective p53 genes in a variety of malignancies, including esophageal (Bennett et al, 1992), breast (Jacquemier et al, 1994) and colon (Dix et al, 1994) cancers known to express p53 protein.…”

ZetaSuite, A Computational Method for Analyzing Multi-dimensional High-throughput Data, Reveals Genes with Opposite Roles in Cancer Dependency

“…In fact, while wildtype TP53 always gave rise to a positive dependency score, reflecting its tumor suppressor function, mutant TP53 produced a negative cancer dependency score, indicating its oncogenic role in those tumor cells (Fig. 6g,h), which is in full agreement with the known functions of wildtype and mutant p53 in tumorigenesis 44 . Most interestingly, as exemplified with MDM2 , we observed that multiple cancer checkpoint genes are also linked to either low CNV or low expression (see Fig.…”